Kottil Rammohan: In fact, there was a very nice presentation at the American Academy of Neurology on a very large number of patients, which found that after vaccination patients on ocrelizumab do not mount an antibody response with the standard Roche platform assay compared to people on other therapies; there was a highly, highly significant p value in terms of the fact that people on ocrelizumab did not make antibodies compared to people on other therapies [ 23 ].
← all excerpts
Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis.
1
—
—